XRAY

DENTSPLY SIRONA Inc. (DENTSPLY International Inc.) - 10-Q Summary

Business Context and Reporting Period

This filing is a Quarterly Report (Form 10-Q) for the period ended June 30, 2009. DENTSPLY International Inc. is the world's largest designer, developer, and manufacturer of professional dental products, operating in more than 120 countries. The company's primary markets are the U.S. and Europe, with approximately 60% of sales generated outside the U.S. The company categorizes its products into Dental Consumables, Dental Laboratory Products, and Dental Specialty Products.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 7.0% ($41.6 million) for the quarter and 8.3% ($95.4 million) for the six months compared to the prior year. Excluding precious metal content, sales declined 5.6% (quarter) and 5.9% (six months).
• Currency Impact: A strengthening U.S. dollar negatively impacted reported sales by 6.1% in the quarter and 6.5% for the six months.
• Internal Growth: Internal growth (excluding currency and acquisitions) was negative 3.9% for the quarter and negative 3.8% for the six months, driven by weaker demand, dealer inventory reductions, and a soft economy.
• Profitability: Net income attributable to DENTSPLY decreased 10.7% for the quarter and 10.1% for the six months. Gross profit margins (excluding precious metals) declined slightly due to unfavorable exchange rates and lower production volumes.
• Restructuring Costs: Restructuring, impairments, and other costs increased to $3.1 million for the quarter and $4.7 million for the six months, compared to $1.5 million and $1.7 million in the prior year periods, respectively.

Guidance, Outlook, and Risks

• Outlook: Management expects to operate below its long-term sustainable internal growth rate of 4-6% in the near future due to adverse economic conditions. However, the dental industry historically performs better than the overall economy.
• Cost Containment: The company is focused on cost containment, operational efficiencies, and restructuring plans initiated in late 2008 and early 2009. Full cost savings from these plans are expected to be realized in 2010.
• Liquidity: The company maintains strong liquidity with $251.9 million in cash and cash equivalents. It has $500 million in available credit under a multi-currency revolving facility and commercial paper program. Long-term debt to total capitalization decreased to 7.8% from 21.2% at year-end 2008.
• Legal Risks: Significant ongoing litigation includes antitrust claims regarding tooth distribution practices (Department of Justice and private class actions) and product liability claims regarding Cavitron ultrasonic scalers. The company states a reasonable estimate of loss cannot be made for current litigation.
• Market Risks: The company is exposed to foreign currency exchange rate fluctuations, interest rate changes, and commodity price volatility (specifically precious metals), which it manages through hedging strategies.

Key Facts for Investor Verification

• Debt Maturity: Verify the status of the $273.9 million in current debt (including private placement notes and commercial paper) maturing within 12 months and management's plan to replace the maturing credit facility.
• Inventory Levels: Monitor dealer inventory reductions, particularly in emerging markets and the U.S. laboratory business, which are cited as a primary driver of negative internal growth.
• Legal Exposure: Track the status of the antitrust class action appeals and the Cavitron product liability class certification motions, as outcomes could result in significant financial liability.
• Restructuring Execution: Confirm the realization of cost savings from the 2009 restructuring plans and the impact on future operating margins.
• Non-Dental Business: Note the significant decline in the non-dental business segment, which contributed to lower sales in the U.S. and Europe.